ACM
LGND icon

Argent Capital Management’s Ligand Pharmaceuticals LGND Stock Holding History

Argent Capital Management’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.2M Buy
3,802
+317
+9% +$74.7K 0.04% 110
2026
Q1 		$696K Buy
+3,485
New +$690K 0.02% 131

Other funds holding LGND

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
JT
Jupiter Topco New York $245B AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Argent Capital Management's LGND Position: Q2 2026 in Review

Argent Capital Management increased its Ligand Pharmaceuticals (LGND) stake by 9.1% in Q2 2026, buying an estimated $74.7K and bringing the position to 3,802 shares worth $1.2M. The position accounts for 0.04% of the portfolio, ranked #110.

Argent Capital Management first reported a position in LGND in Q1 2026 and has held it in 2 quarters since. 415 funds tracked by Wall St. Rank hold LGND as of Q2 2026.

  • Argent Capital Management held 3,802 shares of Ligand Pharmaceuticals worth $1.2M as of Q2 2026.
  • Argent Capital Management bought 317 Ligand Pharmaceuticals shares in Q2 2026, an estimated $74.7K.
  • Ligand Pharmaceuticals made up 0.04% of Argent Capital Management's portfolio in Q2 2026, its #110 holding.
  • Argent Capital Management first reported a position in Ligand Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • 415 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2026.

Based on Argent Capital Management's 13F filing for Q2 2026, filed 15 Jul 2026.